Stocktoria
Coloplast A/S COLO-B.CO
Coloplast A/S (COLO-B.CO) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 5.63% (safety: at-risk). FY2024 revenue was kr 27.0B at a 18.7% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 36 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.005 |
| Retained earnings / assets | 0.32 |
| EBIT / assets | 0.152 |
| Equity / liabilities | 0.595 |
FAQ
Is COLO-B.CO financially healthy?
Coloplast A/S's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does COLO-B.CO pay a dividend, and is it safe?
Yes. Coloplast A/S pays a dividend yielding about 5.63% with a 93.4% payout ratio, rated “at-risk” for safety.
How profitable is COLO-B.CO?
In FY2024, Coloplast A/S had a net margin of 18.7% and a return on equity of 28.2%.
Source: company filings via Yahoo Finance · DK · as of 2024-09-30. Figures in DKK; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.